Autoinjector is available in a Triple Pack
Efficacy for AJOVY

More migraine-free days with as few as 4 injection days a year and results seen as early as one week1,2

Patients experienced significantly more migraine-free days with AJOVY vs placebo in the HALO + Long-Term Extension Studies1,2

See Study Design

Generated with Avocode.Group 2458Rectangle 870 copy 2Path 2293Group 2451Rectangle 870 copyPath 2291Path 2292Rectangle 537Rectangle 537Group 2713Rectangle 534Rectangle 534 copyPath 2279Path 2287Rectangle 534Rectangle 534 copyPath 2289Path 2294linesPath 2288Path 2290Rectangle 517 copyRectangle 517 copy 2Rectangle 517 copy 3Rectangle 517 copy 4Rectangle 517 copy 6Rectangle 517 copy 5Path 2280Path 2281Path 2282Path 2283Path 2284Path 2285Path 2286Path 2548

Consider limitations of Long-Term Extension study design when interpreting efficacy results.

In episodic migraine, a reduction in monthly migraine days was demonstrated during the 12-week period (primary endpoint), with results seen as early as week 11,2

Generated with Avocode.Group 2720Rectangle 870 copy 2Path 2310Group 2459Rectangle 870 copyPath 2308Path 2309Rectangle 537Rectangle 537Group 2721Rectangle 534Rectangle 534 copyPath 2296Path 2297Rectangle 534Rectangle 534 copyPath 2298Path 2311linesPath 2299Path 2300Rectangle 517 copyRectangle 517 copy 2Rectangle 517 copy 3Rectangle 517 copy 4Rectangle 517 copy 6Rectangle 517 copy 5Path 2301Path 2302Path 2303Path 2304Path 2305Path 2306Path 2307Path 2549

Consider limitations of Long-Term Extension study design when interpreting efficacy results.

Patients randomized to quarterly dosing had a mean baseline of 13.2 headache days of at least moderate severity per month and experienced, on average1:
4.7 fewer headache days at month 3 vs 3.3 with placebo (P<0.001).1,2

Patients randomized to monthly dosing had a mean baseline of 12.8 headache days of at least moderate severity per month and experienced, on average1:
5.1 fewer headache days at month 3 vs 3.3 with placebo (P<0.001).1,2

*Reduction in monthly average number of headache days from the Long-Term Extension study was 6.8 with monthly dosing.2

Patients randomized to quarterly dosing had a mean baseline of 9.2 migraine days per month and experienced, on average1:
4.2 fewer migraine days at month 3 vs 3.1 with placebo (P<0.001).1,2

Patients randomized to monthly dosing had a mean baseline of 8.9 migraine days per month and experienced, on average1:
4.3 fewer migraine days at month 3 vs 3.1 with placebo (P<0.001).1,2

*Reduction in monthly average number of migraine days from the Long-Term Extension study was 5.1 with monthly dosing.2

In clinical trials, AJOVY reduced migraine days by 50% or more for some patients1

Secondary endpoint1

Reduction

in monthly number of migrane days with quarterly dosing

37.6% vs 18.1%

with placebo
(P<0.001)

Exploratory analysis2

Reduction

in monthly number of migrane days with quarterly dosing

20% vs 10.4%

with placebo
(Exploratory analysis)

Exploratory analysis2

Reduction

in monthly number of migrane days with quarterly dosing

7.7% vs 4.2%

with placebo
(Exploratory analysis)

Secondary endpoint1

Reduction

in monthly number of migrane days with quarterly dosing

44.4% vs 27.9%

with placebo
(P<0.001)

Exploratory analysis2

Reduction

in monthly number of migrane days with quarterly dosing

25.8% vs 15.4%

with placebo
(Exploratory analysis)

Exploratory analysis2

Reduction

in monthly number of migrane days with quarterly dosing

8.5% vs 4.5%

with placebo
(Exploratory analysis)

Similar reductions seen with monthly dosing in chronic migraine patients

With monthly dosing, reduction in monthly average headache days of at least moderate severity: 40.8% of patients achieved a ≥50% reduction vs 18.1% with placebo (P<0.001), 20.6% achieved a ≥75% reduction vs 10.4% with placebo (exploratory analysis), and 7.5% achieved 100% reduction vs 4.2% for placebo (exploratory analysis).1,2

Similar reductions seen with monthly dosing in episodic migraine patients

With monthly dosing, reduction in monthly average migraine days: 47.7% of patients achieved a ≥50% reduction vs 27.9% with placebo (P<0.001), 27.2% achieved a ≥75% reduction vs 15.4% with placebo (exploratory analysis), and 10.1% achieved 100% reduction vs 4.5% for placebo (exploratory analysis).1,2

What to explore next